Pfizer Silences Testimony On Short-Term Prempro Use
Plaintiffs in multidistrict litigation over Pfizer Inc.'s hormone replacement drug Prempro cannot present expert testimony that short-term use of the drug increases breast cancer risk, a judge has ruled on the...To view the full article, register now.
Already a subscriber? Click here to view full article